Trial explores potential of lesser known cannabinoid
Orenda Hemp’s trial of different hemp strains puts a spotlight on CBG (Cannabigerol), the cannabinoid that has historically languished in the shadow of CBD.
Almost 40% of the hemp strains in the Southern Virginia Regional Trial are dedicated to strains with a higher proportion of CBG, which generally occurs in small quantities in the plant.
Despite being a minor cannabinoid, research has shown the potential of CBG to fight cancer and help with other conditions such as inflammatory bowel disease, glaucoma and Huntington’s Disease.
The trial’s focus on CBG-rich strains aims to assist Hemp Derived Cannabis (HDC) researchers in developing precision hemp driven therapeutics. Precision HDC uses combinations of cannabinoids terpenes and flavonoids that target specific health profiles. Being able to include CBG in the mix for our research and development partners, Medlogia, allows for more powerful combinations than CBD alone.